Advanced search
Start date
Betweenand

FAPESP/MMV/DNDi/UNICAMP/USP Consortium to discover new drugs for the treatment of tropical parasitic diseases

Grant number: 15/50655-9
Support Opportunities:Research Grants - Research Partnership for Technological Innovation - PITE
Duration: January 01, 2020 - December 31, 2025
Field of knowledge:Physical Sciences and Mathematics - Chemistry - Organic Chemistry
Principal Investigator:Luiz Carlos Dias
Grantee:Luiz Carlos Dias
Host Institution: Instituto de Química (IQ). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
City: Campinas
Partner institutions: Medicines for Malaria Venture
Pesquisadores principais:
Leonardo Luiz Gomes Ferreira
Associated scholarship(s):24/03676-0 - Drug discovery of pre-clinical candidates for Chagas Disease, BP.PD
24/00815-9 - Development of preclinical candidates for the treatment of malaria within the scope of the MINDI consortium, BP.PD
23/15953-5 - Development of pre-clinical candidates for the treatment of Chagas Disease within the scope of the MINDI consortium, BP.PD
+ associated scholarships 23/12973-5 - Development of preclinical candidates for the treatment of malaria within the scope of the MINDI consortium, BP.PD
23/10723-1 - Drug discovery of pre-clinical candidates for Chagas Disease, BP.PD
23/10724-8 - Drug discovery of pre-clinical candidates for Chagas Disease, BP.PD
22/11772-3 - Drug discovery of a pre-clinical candidate for malaria, BP.PD
22/10577-2 - Drug discovery of pre-clinical candidates for Chagas Disease at the MINDI consortium, BP.PD
22/10574-3 - Drug discovery of pre-clinical candidates for Chagas Disease, BP.PD
21/02761-5 - Drug discovery for the treatment of Chagas Disease within the MINDI Consortium, BP.PD
20/14429-2 - Discovery of plasmodium inhibitors as clinical candidates to treat Malaria, BP.PD
20/10494-4 - Drug discovery in the fight against Malaria, BP.PD
20/10493-8 - Synthesis of compounds for the treatment of Chagas Disease within the MINDI consortium, BP.PD - associated scholarships

Abstract

We propose to establish a FAPESP/MMV/DNDi/UNICAMP/USP consortium with the ultimate goal to discover novel drug candidates for clinical development. To this end, the consortium will place high priority on selecting team members from the state of Sao Paulo with a proven track record of high quality research. This group will work in collaboration with expert scientists from the Drugs for Neglected Diseases initiative (DNDi, www.dndi.org) and Medicines for Malaria Venture (MMV, www.mmv.org) and have access to a very well organized framework providing an integrated approach to modern drug discovery. The overall goal with MMV is to deliver a clinical candidate to treat malaria, as defined by the criteria for an MMV Preclinical candidate. Such a compound should have the potential to be developed, in combination, to deliver a Single Exposure Radical Cure and Prophylaxis or single exposure chemoprotection drug. (AU)

Articles published in Pesquisa FAPESP Magazine about the research grant:
An agenda for forgotten diseases 
Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (5)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
KOOVITS, PAUL J.; DESSOY, MARCO A.; MATHEEUSSEN, AN; MAES, LOUIS; CALJON, GUY; FERREIRA, LEONARDO L. G.; CHELUCCI, RAFAEL C.; MICHELAN-DUARTE, SIMONE; ANDRICOPULO, ADRIANO D.; CAMPBELL, SIMON; et al. Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents. RSC MEDICINAL CHEMISTRY, v. 11, n. 11, p. 1267-1274, . (15/50655-9, 15/19495-5, 13/07600-3)
RAMON GUERRA DE OLIVEIRA; LUIZA DOS REIS CRUZ; LUIZ CARLOS DIAS. ARTEMISININA E DERIVADOS: DESCOBERTA, ESTRATÉGIAS SINTÉTICAS E OBTENÇÃO INDUSTRIAL. Química Nova, v. 45, n. 7, p. 831-846, . (15/50655-9, 18/24344-4, 13/07600-3)
DE OLIVEIRA REZENDE JR, CELSO; MARTINEZ, PABLO DAVID GRIGOL; FERREIRA, RAFAEL AUGUSTO ALVES; KOOVITS, PAUL JOHN; SOARES, BRUNA MIRANDA; FERREIRA, LEONARDO L. G.; MICHELAN-DUARTE, SIMONE; CHELUCCI, RAFAEL CONSOLIN; ANDRICOPULO, ADRIANO D.; MATHEEUSSEN, AN; et al. Hit-to-lead optimization of a 2-aminobenzimidazole series as new candidates for chagas disease. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v. 246, p. 10-pg., . (13/07600-3, 15/50655-9, 15/09080-2)
ALVES FERREIRA, RAFAEL AUGUSTO; REZENDE JUNIOR, CELSO DE OLIVEIRA; GRIGOL MARTINEZ, PABLO DAVID; KOOVITS, PAUL JOHN; SOARES, BRUNA MIRANDA; FERREIRA, LEONARDO L. G.; MICHELAN-DUARTE, SIMONE; CHELUCCI, RAFAEL CONSOLIN; ANDRICOPULO, ADRIANO D.; GALUPPO, MARIANA K.; et al. 2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. PLoS Neglected Tropical Diseases, v. 15, n. 2, . (15/09080-2, 15/50655-9, 13/07600-3)
KOOVITS, PAUL J.; DESSOY, MARCO A.; MATHEEUSSEN, AN; MAES, LOUIS; CALJON, GUY; MOWBRAY, CHARLES E.; KRATZ, JADEL M.; DIAS, LUIZ C.. Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorganic & Medicinal Chemistry Letters, v. 30, n. 1, . (13/07600-3, 15/50655-9, 15/19495-5)

Please report errors in scientific publications list using this form.